Psychedelics Weekly – Research Explained: Ket...

Denver mushroom decriminalization changed the national conversation around psilocybin access, personal use, and grassroots psychedelic reform. In this episode of Psychedelics Today, Joe Moore speaks with Travis Tyler Fluck, an autognostic mycologist, educator, activist, end-of-li ...  Show more

Aspen Psychedelic Symposium is the focus of this conversation with Martha Hammel of the Aspen Psychedelic Resource Center and Tasia Poinsatte of Healing Advocacy Fund. They join Joe Moore to discuss this year's symposium, how it fits into Colorado's evolving natural medicine land ...  Show more

Psychiatrist and psychedelics and bipolar researcher Dr. Josh Woolley (University of California San Francisco), and peer researcher Amir speak on psilocybin, ketamine, and psychedelics and their links with bipolar disorder, and what the science says about psychedelics as treat ...

This episode I discuss medical research on psychedelic compounds with Dr. Matthew Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins School of Medicine. We discuss the biology and medical clinical-trial uses of psilocybin, MDMA, ayahuasca, DMT, and L ...  Show more

We’re in the midst of a psychedelic renaissance, where this once demonized class of drugs is now front and center receiving attention among entrepreneurs, investors, clinical trials and even patients. In this special conversation, TED Health’s Dr. Shoshana Ungerleider speaks with ...  Show more

Dr. Paul Liknaitsky is the head of clinical psychedelic research at Monash University Australia. He is conducting world-first clinical trials into the use of magic mushrooms and ecstasy to treat depression, anxiety, and PTSD. This is his second time on this podcast to chat about ...  Show more